Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Hiroyuki Shimada et al.|Nature Medicine|2023Cited by 125
Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyRochelle Bagatell, Lisa Hang, Steven G. DuBois et al.|Journal of the National Comprehensive Cancer Network|2024Cited by 47